Brain implant startup Science Corp secures 400M USD to bring vision chip to market

Executive Briefing
“Brain-computer interface startup Science Corp has raised 400 million USD in a Series D...”
Key Takeaways
- 1.Brain-computer interface company Science Corp revealed it has raised 400 million USD in a Series D funding round that brings its valuation to 3.5 billion USD.
- 2.The round was led by venture capital firm Khosla Ventures, with participation from the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.
- 3.The funding provides capital to bring its flagship PRIMA product to market, a specialized chip implanted in the eyes of patients suffering from age-related macular degeneration.
Brain-computer interface startup Science Corp has raised 400 million USD in a Series D funding round to bring its flagship medical device PRIMA to international markets.
Financial Context & Deal Developments
Brain-computer interface company Science Corp revealed it has raised 400 million USD in a Series D funding round that brings its valuation to 3.5 billion USD.
The round was led by venture capital firm Khosla Ventures, with participation from the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.
The funding provides capital to bring its flagship PRIMA product to market, a specialized chip implanted in the eyes of patients suffering from age-related macular degeneration.
Market Impact & Financial Analysis
Securing a substantial capital injection demonstrates continued investor appetite for neurotechnology ventures with medical products approaching commercialization milestones.
The strategy to leverage expedited pathways in the U.S. alongside European traction reflects an industry-wide effort to navigate complex regulatory hurdles for implants.
Market Outlook & Key Factors to Watch
The company has not disclosed the out-of-pocket price patients will be charged for treatments at Moorfields Private Eye Hospital in London.
Science Corp has not disclosed the specific condition it first intends to treat with its direct brain implant pipeline named Biohybrid.







